Global Blood Therapeutics Finds $40.7M For Sickle Cell Treatments

San Francisco-based Global Blood Therapeutics said this week that it has raised $40.7M in a Series A financing, for its efforts to develop oral, small molecule drugs for treating conditions such as sickle cell disease. The funding came from Third Rock Ventures. Global Blood's founders include Charles Homcy, and Craig Muir of Third Rock, David Phillips, co-founder of COR Therapeutics, and University of California, San Francisco researchers Matthew Jacobson, Andrej Sali, and Jack Taunton. More information »